CALCIBRONAT
PROPHARMAL
Identification
- Active ingredient (INN)
- BROMO-GALACTOGLUCONATE DE CALCIUM
- Internal code
- 16 G 163
- Country of Origin
- Algeria
- Pharmaceutical form
- Effervescent Tablet
- Prescription List
- OTC
- Packaging
- boite de 01 tube de 20 comprime
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Additional treatment of mild sleep disorders, irritability, nervousness.
Associated Conditions
Special warnings if treatment is not possible The occurrence of skin manifestations and/or neuropsychic disorders requires immediate discontinuation of treatment.
This medication contains sucrose.
It is not recommended for use in patients with sucrose intolerance.
Precautions for use.
- Lsabsorption of alcohol during treatment is not recommended.
- The elderly is more susceptible to the risk of neuropsychic effects, especially in patients with renal impairment, even moderate.
- This medicine contains 482 mg sodium per dose of 2 tablets s effervescent s (ma ximale posology) , which corresponds to 24% of the maximum daily dietary intake recommended by WHO of 2 g sodium per adult.
This medicine is therefore considered to be a high sodium content.
Therefore, this medication is considered to be a low-sodium content.
Therefore, it must be taken into account for patients with low-sodium content.
This medication contains 10 mmol sodium-element, i.e. 241 mg per tablet effervescent.
To be taken into account in patients with a low-sodium content of the medication, i. a low-sodium content of the medication, i. a low-sodium content of the medication.
Mechanism of Action
Pharmacotherapeutic group
HYPNOTIC AND SEDATIFI (N: Central Nervous System).
Bromoxcalcic combination, combining the sedative action of bromine and the peripheral action of calcium on neuromuscular excitability.
Adverse Effects
Very rare bromide-like skin accidents have been reported after prolonged treatment.
- Neuropsychic disorders: daytime somnolence, confusion, temporal disorientation, irritability, hallucinations.
These effects are particularly observed in the elderly or at high doses.
- Digestive disorders: anorexia, constipation.
Reporting suspected adverse reactions
Reporting suspected adverse reactions after authorization of the drug is important.
It allows for continuous monitoring of the benefit/risk ratio of the drug.
Health professionals report any suspected adverse reactions via the national reporting system: National Drug and Health Products Safety Agency (ANSM) and Network of Regional Pharmacovigilance Centres.